Exenatide for Myocardial Protection During Reperfusion Study

NCT01938235 · Unknown status

Last updated 2026-05-28

This clinical trial is testing whether the drug exenatide can help protect the heart muscle in adults who have had a heart attack during the process of restoring blood flow.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 198 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2014-02 · est. completion 2018-01

Where 10 sites · Canada

What this study is testing ClinicalTrials.gov NCT01938235 ↗

Description as written by the study sponsor.

This study aims to assess the effect of exenatide on myocardial injury in patients undergoing emergent percutaneous coronary intervention (PCI) for ST segment elevation myocardial infarction or heart attack (STEMI).

Treatments tested

Exenatide also known as Byetta Drug

Intravenous bolus and 24-hour infusion of exenatide
Placebo Drug

Intravenous bolus and 24-hour infusion of placebo

Main thing measured	Ratio of final infarct size at 3 months over area at risk at 72 hours post randomization (using cMRI)
Sponsor	University Health Network, Toronto
Conditions studied	Myocardial Infarction
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01938235 ↗